Yonsei Med J.  2005 Feb;46(1):42-50. 10.3349/ymj.2005.46.1.42.

Plasma Adiponectin and Insulin Resistance in Korean Type 2 Diabetes Mellitus

• Kim MJ
• Yoo KH
• Park HS
• Chung SM
• Jin CJ
• Lee Y
• Shin YG
• Chung CH

• KMID: 2158111
• DOI: http://doi.org/10.3349/ymj.2005.46.1.42

Abstract

Insulin resistance, which implies impairment of insulin signaling in the target tissues, is a common cause of type 2 diabetes. Adipose tissue plays an important role in insulin resistance through the dysregulated production and secretion of adipose-derived proteins, including tumor necrosis factor-alpha, plasminogen activator inhibitor-1, leptin, resistin, angiotensinogen, and adiponectin. Adiponectin was estimated to be a protective adipocytokine against atherosclerosis, and also to have an anti-inflammatory effect. In this study, the relationship between fasting plasma adiponectin concentration and adiposity, body composition, insulin sensitivity (ITT, HOMAIR, QUICK), lipid profile, fasting insulin concentration were examined in Korean type 2 diabetes. The difference in the adiponectin concentrations was also examined in diabetic and non-diabetic subjects, with adjustment for gender, age and body mass index. 102 type 2 diabetics and 50 controls were examined. After a 12-h overnight fast, all subjects underwent a 75gram oral glucose tolerance test. Baseline blood samples were drawn for the determinations of fasting plasma glucose, insulin, adiponectin, total cholesterol, triglyceride, LDL-cholesterol, and HDL-cholesterol. The body composition was estimated using a bioelectric impedance analyzer (Inbody 2.0). The insulin sensitivity was estimated using the insulin tolerance test (ITT), HOMAIR and QUICK methods. In the diabetic group, the fasting adiponectin concentrations were significantly lower in men than in women. They were negatively correlated with BMI (r=-0.453), hip circumference (r=-0.341), fasting glucose concentrations (r=-0.277) and HOMAIR (r=-0.233). In addition, they were positively correlated with systolic blood pressure (r=0.321) and HDL-cholesterol (r= 0.291). The systolic blood pressure and HDL-cholesterol were found to be independent variables, from a multiple logistic regression analysis, which influenced the adiponectin concentration. Compared with the non-diabetic group, the adiponectin concentrations were significantly lower in the diabetic group, with the exception of obese males. In conclusion, the plasma adiponectin concentrations were closely related to the insulin resistance parameters in Korean type 2 diabetic patients.

Keyword

Diabetes mellitus; insulin resistance; adiponectin

MeSH Terms

Adult
Aged
Biological Markers
Diabetes Mellitus, Type 2/*blood
Female
Humans
*Insulin Resistance
Intercellular Signaling Peptides and Proteins/*blood
Korea
Male
Middle Aged

Figure

• 

  Fig. 1 Adiponectin concentration difference between diabetic and non-diabetic patients, with adjustment for age, gender and BMI.

Reference

1. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 1996. 2:800–802.

2. Spiegelman BM, Flier JS. Adipogenesis and obesity: rounding out the big picture. Cell. 1996. 87:377–389.

3. Christian W, Tohru F, Sachiyo T, Kikuko H, Yuji M, Richard E, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001. 86:1930–1935.

4. Wei-shiung Y, Yuji M, Chi-Yuan J, Jao-Ping W, Ta-Jen W, Chi-Ling C, et al. Synthetic peroxisome proliferator activated receptor-α agonist, rosiglitazone, increase plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 2002. 25:376–380.

5. Ouchi N, Kihara S, Arita Y, Maeda Kuriyama H, Okamoto Y, Hotta Nishida M, et al. Novel modulator for endothelial adhesion molecules: adipocyte derived plasma protein adiponectin. Circulation. 1999. 100:2473–2476.

6. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999. 257:79–83.

7. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a newel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000. 20:1595–1599.

8. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001. 7:941–946.

9. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappa B signaling through a cAMP-dependent pathway. Circulation. 2000. 102:1296–1301.

10. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000. 85:2402–2410.

11. Kim EJ, Min HK, Choi YK, Huh KB, Shin SH. Diabetes. 1998. 2th ed. Korean Diabetes Association: Korea medical publishing co.

12. Hotamisligil GS, Spiegelman BM. Tumor-necrosis factor α: a key component of the obesity-diabetes link. Diabetes. 1994. 43:1271–1278.

13. Hotamisligil GS, Murray DL, Choy LS, Spiegelman BM. Tumor necrosis factor-α inhibits signaling from the insulin receptor. Proc Natl Acad Sci. 1994. 91:4854–4858.

14. Alwssi MC, Peiretti F, Morange P, Henry M, Nalbone G, Juhan-vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible line between visceral fat accumulation and vascular disease. Diabetes. 1997. 46:860–867.

15. Yudkin JS, Kumari M, Humphries SE, Mohammed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis. 2000. 148:209–214.

16. Weyer C, Tataranni PA, Pratley RE. Insulin action and insulinemia are closely related to the fasting complement C₃, but not acylation-stimulating protein concentration. Diabetes Care. 2000. 23:779–785.

17. Maeda K, Okubo K, Ahimomura I, Funahashi T, Matsuzawa Y, Matsubara K. cDNA cloning and expression of a novel adipose-specific collagen-like factor, apM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun. 1996. 221:286–289.

18. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995. 270:26746–26749.

19. Hu E, Liang P, Spiegelman BM. Adipo Q is a novel adipose-specific gene dysregulated in obesity. J Biol Chem. 1996. 18:10697–10703.

20. Takahashi M, Arita Y, Yamagata K, Matsukawa Y, Okutomi K, Horie M, et al. Genomic structure and mutations in adipose-specific gene, adiponectin. Int J Obes Relat Metab Disord. 2000. 24:861–868.

21. Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol. 1998. 12:335–338.

22. Yokota T, Oritani K, Takahashi I, Ishikana J, Matsuyama A, Ouchi N, et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the function of macrophages. Blood. 2000. 96:1723–1732.

23. Statnick MA, Beavers LS, Conner LJ, Corominola H, Johnson D, Hammond CD, et al. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res. 2000. 1:81–88.

24. Fruebis J, Taso TS, Javorschi S, Ebbets-Reet D, Erickson MR, Yen FT, et al. Proteolytic cleavage product of 30 kd adipocyte complement-related protein increase fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci. 2001. 98:2005–2010.

25. Berg AH, Combs TP, Du X, Brownlee M, Scherer P. The adipocyte-secreted protein Acrp 30 enhances hepatic insulin action. Nat Med. 2001. 7:947–953.

26. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 2001. 86:3815–3819.

27. Nishizawa T, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte derived protein. Diabetes. 2002. 51:2734–2741.

28. DeFronzo RA, Tobin JD, Andres R. The glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979. 237:E214–E223.

29. Akinmokun A, Selby PL, Ramaiya K, Alberti KGMN. The short insulin tolerance test for the determination of insulin sensitivity: A comparison with the euglycemic clamp. Diabet Med. 1992. 9:432–437.

30. Hirst S, Phillips DIW, Vines SK, Clark PM, Hales CN. Reproducibility of the short insulin tolerance test. Diabet Med. 1993. 10:839–842.

31. Grulet H, Durlach V, Hecart AC, Gross A, Leutenegger M. Study of the rate of early glucose disappearance following insulin injection: insulin sensitivity index. Diabetes Res Clin Pract. 1993. 20:201–207.

32. Park SW, Yun YS, Ahn CW, Kwon SH, Nam JH, Han SH, et al. Short insulin tolerance test (SITT) for the determination of in vivo insulin sensitivity- a comparison with euglycemic clamp test. J Korean Diabetes Assoc. 1999. 22:199–208.

33. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: application and validation of recent suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 2002. 156:1070–1077.

34. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001. 86:1930–1935.

35. Park KG, Park KS, Kim MJ, Kim HS, Suh YS, Ahn JD, et al. Relationship between serum adiponectin and leptin concentrations and body fat distribution. Diabetes Res Clin Pract. 2004. 63:135–142.

36. Yatagai T, Nagasaka S, Taniguchi A, Fukushima M, Nakamura T, Kuroe A, et al. Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism. 2003. 52:1274–1278.

37. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens. 2003. 16:72–75.

38. Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, et al. Adiponectin in essential hypertension. J Nephrol. 2002. 15:507–511.

39. Matsubara M, Maruka S, Katayose S. Inverse relationship between plasma adiponectin and leptin concentration in normal-weight and obese women. Eur J Endocrinol. 2002. 147:173–180.